Contrasting NKGen Biotech (NKGN) and Its Competitors

NKGen Biotech (NYSE:NKGN) is one of 280 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare NKGen Biotech to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares NKGen Biotech and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.08
NKGen Biotech Competitors	$569.56 million	-$31.32 million	-42.97

NKGen Biotech’s peers have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

NKGen Biotech has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s peers have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.

Insider & Institutional Ownership

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares NKGen Biotech and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-5,175.29%	-173.59%	-43.23%

Analyst Recommendations

This is a summary of current ratings for NKGen Biotech and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	N/A
NKGen Biotech Competitors	1582	4717	12221	236	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 63.78%. Given NKGen Biotech’s peers higher probable upside, analysts clearly believe NKGen Biotech has less favorable growth aspects than its peers.

NKGen Biotech Company Profile

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.